317 THE ECONOMIC BURDEN OF INTERSTITIAL CYSTITIS AND PAINFUL BLADDER SYNDROME
| Autor: | LB Montejano, Greg Lenhart, Kimberly Ruiz, Rebecca Robinson |
|---|---|
| Rok vydání: | 2011 |
| Předmět: | |
| Zdroj: | Journal of Urology. 185 |
| ISSN: | 1527-3792 0022-5347 |
| DOI: | 10.1016/j.juro.2011.02.2636 |
| Popis: | INTRODUCTION AND OBJECTIVES: Interstitial cystitis (IC) and painful bladder syndrome (PBS) are related conditions, affecting 1–17% of women and 0.25–5% percent of men (Clemens et al. J Urol 2005; Clemens et al. J Urol 2007; Ibrahim et al. Int Urol Nephrol 2007). Many people with IC/PBS symptoms do not seek treatment, but previous research suggests IC/PBS healthcare costs are significant. This study was undertaken to identify costs and cost drivers associated with IC/PBS. METHODS: Adult patients newly diagnosed with IC/PBS between January 2005 and March 2008 were identified from healthcare claims in the MarketScan® Research Databases and matched to controls without evidence of IC/PBS on the basis of age, gender, geographic region and insurance type. The two cohorts were compared on baseline clinical characteristics, and healthcare utilization and costs over a 12-month period following diagnosis of IC/PBS. Multivariate analyses controlled for baseline differences between cohorts that remained after matching. RESULTS: The IC/PBS cohort (n 17,604) was predominantly female (86.3%), with a mean age of 52.2 years. IC/PBS patients were more likely than matched controls to have pre-diagnosis evidence of dysuria (12.8% vs. 1.0% ), acute cystitis (6.2% vs. 0.6% ) and vaginitis (7.6% vs. 1.9% ). Baseline comorbidities more common in IC/PBS patients included chronic lower back pain (17.5% vs. 8.4% ), osteoarthritis (12.1% vs. 8.1% ), depression (9.2% vs. 5.2% ) and fibromyalgia (5.3% vs. 2.0% ). More IC/PBS patients than controls filled prescriptions in the 12 months post-diagnosis for NSAIDs (27.2% vs. 18.3% ), weak opioids (23.3% vs. 10.4% ), strong opioids (44.5% vs. 23.1% ), antidepressants (41.1% vs. 22.2% ) and benzodiazepines (26.4% vs. 12.7% ). Mean annual costs were $3,114 higher for IC/PBS patients ($11,067 vs. $7,953 ). After baseline adjustment, IC/PBS patients incurred higher costs across all cost elements including inpatient, ER, outpatient and pharmacy settings. p 0.001. CONCLUSIONS: In the year preceding diagnosis, IC/PBS patients had higher rates of several urological conditions than controls, suggesting treatment for IC/PBS symptoms may precede an actual diagnosis. More IC/PBS patients than controls had potentially costly comorbid conditions. Even after controlling for presence of these comorbidities, however, IC/PBS utilized more healthcare services and incurred higher costs than patients without the condition. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|